ArticleIn silico pharmacology2025
Designing a novel mRNA vaccine against foot-and-mouth disease using immunoinformatics approach.
Article in In silico pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Foot-and-mouth disease (FMD) is a highly contagious disease of cloven-footed animals and has primarily been controlled through vaccination. The main disadvantages of the currently used whole virus-based inactivated vaccines are lack of immunological memory and requirement of strict bio-containment facility for upscaling the virus. In order to lower the burden of FMD, development of novel and potent vaccines is of paramount importance. Thus, this study resorted to immunoinformatics to design a multi-epitope- based mRNA vaccine that would protect against the FMD virus serotypes O, A, and Asia1. Several immunoinformatics tools were utilized to predict T and B-cell epitopes present on the capsid protein of FMD virus. These predicted epitopes were passed through a computational approach comprised of antigenicity, toxicity, allergenicity, and other biochemical properties-based prediction and analyses. Further, molecular docking and simulation among the predicted epitopes and MHC molecules was carried out to identify the key epitopes and MHC molecules. The structural analysis of antigenic epitopes and MHC alleles revealed their structures and binding sites. The seven predicted epitopes, a highly immunogenic adjuvant, secretion booster, and appropriate linkers, namely GPGPG and EAAAK, were combined to design the mRNA vaccine. The physicochemical analytical findings indicated that the vaccine construct found to be antigenic, almost neutral at physiological pH, non-toxic, non-allergenic, stable, and capable of generating a robust immune response. The findings of this comprehensive study demonstrated that this vaccine construct could pave the way for successfully combating infections caused by the economically important FMD virus. Supplementary Information: The online version contains supplementary material available at 10.1007/s40203-025-00444-z.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.